GENFIT: Information relating to the shareholders meeting of June 11, 2020
08 Juin 2020 - 6:20PM
GENFIT: Information relating to the shareholders meeting of June
11, 2020
Lille (France), Cambridge
(Massachusetts, United States), June 8, 2020 – GENFIT
(Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company
dedicated to improving the lives of patients with metabolic and
chronic liver diseases, today announced that the June 11, 2020
Annual Shareholders meeting, which will be conducted in a virtual
format only, will be broadcast live on the Company’s website.
The Company also announced the members of the Shareholders Meeting
committee (bureau de l’Assemblée) .
As previously announced, due to the ongoing
COVID-19 pandemic and in accordance with emergency measures imposed
by the French government, the Board of Directors of the Company
decided that the Annual Meeting will be conducted in a virtual
format only on June 11, 2020 at 10:00 am CEST at the Company’s
headquarters located at Parc Eurasanté, 885 Avenue Eugène Avinée,
Loos (59120), France, without the physical presence of shareholders
and others who are usually entitled to attend.
This Annual Shareholders Meeting will be chaired
by Mr. Jean-François Mouney, Chairman of the Board of Directors and
will be broadcast live in audio format on the Company’s website
(https://ir.genfit.com)
Given the current pandemic, and in accordance
with the French regulatory authorities, article 8 of the April 10,
2020 decree number 2020-418, the Board of Directors has appointed
Mr. Xavier Guille des Buttes, Vice-Chairman of the Board of
Directors, and Mr. Carl-Stefan Piétin, Employee Representative to
the Board of Directors, as scrutineers (scrutateurs) of the Annual
Shareholders Meeting.
Shareholders Meeting broadcast
details
Shareholders will be able to attend the virtual
format through the Investors section of the website
(https://ir.genfit.com) under the Events section and on the
Shareholders Meeting page under Financials. A recording will be
made available on the Company’s website after the meeting.
ABOUT GENFIT
GENFIT is a late-stage biopharmaceutical company
dedicated to the discovery and development of innovative
therapeutic and diagnostic solutions in metabolic and liver related
diseases where there are considerable unmet medical needs,
corresponding to a lack of approved treatments. GENFIT is a leader
in the field of nuclear receptor-based drug discovery, with a rich
history and strong scientific heritage spanning more than two
decades. Its most advanced drug candidate, elafibranor, is
currently being evaluated in a pivotal Phase 3 clinical trial
(“RESOLVE-IT”) as a potential treatment for NASH and GENFIT plans
to initiate a Phase 3 clinical trial of elafibranor in patients
with PBC. As part of GENFIT’s comprehensive approach to clinical
management of patients with NASH, the Company is also developing a
new, non-invasive blood-based diagnostic technology, NIS4™, to
enable non-invasive identification of patients with NASH and
significant fibrosis. With facilities in Lille and Paris, France,
and Cambridge, MA, USA, the Company has approximately 200
employees. GENFIT is a publicly traded company listed on the Nasdaq
Global Select Market and on compartment B of Euronext’s regulated
market in Paris (Nasdaq and Euronext: GNFT). www.genfit.com
CONTACT
GENFIT | Investors
Naomi EICHENBAUM – Investor Relations | Tel: +1
(617) 714 5252 | investors@genfit.com
PRESS RELATIONS | Media
Hélène LAVIN – Press relations | Tel: +333 2016
4000 | helene.lavin@genfit.com
- GENFIT: Information relating to the shareholders meeting of
June 11, 2020
Genfit (EU:GNFT)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Genfit (EU:GNFT)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024